ATRA

9.92

3.41% -0.35

Dopo l'orario di chiusura: 9.92

Atara Biotherapeutics Inc (ATRA)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché ATRA Giù? Forum Previsione

Precedente Chiudi:

$10.27

Aprire:

$10.18

Volume 24 ore:

69,039

Relative Volume:

0.05

Capitalizzazione di mercato:

$89.38M

Reddito:

$23.14M

Utile/perdita netta:

$-9.47M

Rapporto P/E:

-11.24

EPS:

-0.8827

Flusso di cassa netto:

$-25.88M

1 W Prestazione:

-5.61%

1M Prestazione:

+108.40%

6M Prestazione:

-30.77%

1 anno Prestazione:

+17.81%

Intervallo 1D:

$9.8273

$10.18

Intervallo di 1 settimana:

$9.35

$10.65

Portata 52W:

$3.92

$19.14

Atara Biotherapeutics Inc Stock (ATRA) Company Profile

Nome

Atara Biotherapeutics Inc

Settore

Healthcare (1102)

Industria

Biotechnology (614)

Telefono

805-623-4211

Indirizzo

1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA

Dipendente

Cinguettio

@Atarabio

Prossima data di guadagno

2026-05-21

Ultimi documenti SEC

ATRA's Discussions on Twitter

Compare ATRA vs VRTX, REGN, ARGX, ALNY, RVMD

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
ATRA Atara Biotherapeutics Inc	9.92	92.53M	23.14M	-9.47M	-25.88M	-0.8827
VRTX Vertex Pharmaceuticals Inc	446.83	112.12B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	635.45	65.92B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	891.32	52.38B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	303.05	40.54B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	149.23	33.10B	742.00K	-1.37B	-1.07B	-7.0731

Atara Biotherapeutics Inc Stock (ATRA) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-01-13	Downgrade	Canaccord Genuity	Buy → Hold
2023-11-09	Downgrade	Evercore ISI	Outperform → In-line
2023-11-09	Downgrade	H.C. Wainwright	Buy → Neutral
2023-11-09	Downgrade	Mizuho	Buy → Neutral
2022-07-20	Downgrade	Citigroup	Neutral → Sell
2022-07-13	Downgrade	JP Morgan	Overweight → Neutral
2022-07-13	Downgrade	Stifel	Buy → Hold
2022-05-10	Downgrade	Citigroup	Buy → Neutral
2021-05-13	Aggiornamento	JP Morgan	Neutral → Overweight
2020-12-09	Downgrade	Citigroup	Buy → Neutral
2020-12-08	Reiterato	H.C. Wainwright	Buy
2020-11-10	Reiterato	H.C. Wainwright	Buy
2020-06-30	Iniziato	Evercore ISI	Outperform
2020-06-15	Iniziato	H.C. Wainwright	Buy
2020-04-23	Aggiornamento	Citigroup	Neutral → Buy
2019-11-08	Downgrade	JP Morgan	Overweight → Neutral
2019-09-27	Downgrade	Goldman	Neutral → Sell
2019-09-16	Downgrade	Jefferies	Buy → Hold
2019-06-04	Aggiornamento	Citigroup	Sell → Neutral
2019-05-30	Iniziato	ROTH Capital	Buy
2019-05-23	Iniziato	Stifel	Buy
2019-01-23	Iniziato	Mizuho	Buy
2018-04-10	Iniziato	JP Morgan	Overweight
2018-03-16	Iniziato	Guggenheim	Neutral
2018-03-05	Reiterato	Jefferies	Buy
2018-02-28	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
2018-02-15	Downgrade	Citigroup	Neutral → Sell
2018-01-03	Aggiornamento	Citigroup	Sell → Neutral
2017-10-06	Ripresa	Goldman	Neutral

Mostra tutto

Atara Biotherapeutics Inc Borsa (ATRA) Ultime notizie

02:36 AM

ATRA stock shoots up 82% in a month: Here's what you should know - MSN

02:36 AM

Jun 04, 2026

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire

Jun 04, 2026

2026-06-04 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Stockholders to Learn More About the Investigation | NDAQ:ATRA | Press Release - Stockhouse

Jun 04, 2026

Jun 03, 2026

Atara Biotherapeutics, Inc. Common Stock (ATRA) Stock Price Today & Analysis - Gotrade

Jun 03, 2026

ATRA News | ATARA BIOTHERAPEUTICS INC (NASDAQ:ATRA) - ChartMill

Jun 03, 2026

Jun 02, 2026

Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Investors to Inquire about Securities Investigation - ACCESS Newswire

Jun 02, 2026

Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeuti - The National Law Review

Jun 02, 2026

May 31, 2026

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Reach Out - ACCESS Newswire

May 31, 2026

2026-05-31 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Reach Out | NDAQ:ATRA | Press Release - Stockhouse

May 31, 2026

May 28, 2026

How (ATRA) Movements Inform Risk Allocation Models - Stock Traders Daily

May 28, 2026

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Atara Biotherapeutics, Inc. (ATRA) And Encourages Stockholders to Reach Out - ACCESS Newswire

May 28, 2026

2026-05-28 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Atara Biotherapeutics, Inc. (ATRA) And Encourages Stockholders to Reach Out | NDAQ:ATRA | Press Release - Stockhouse

May 28, 2026

May 26, 2026

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 22, 2026 in Atara Biotherapeutics, Inc. LawsuitATRA - Morningstar

May 26, 2026

May 24, 2026

ATRA FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026 - New Castle News

May 24, 2026

May 22, 2026

Atara Biotherapeutics Analyst Ratings and Price Targets | NASDAQ:ATRA - Benzinga

May 22, 2026

ATRA DEADLINEFINAL REMINDER: Bronstein, Gewirtz & Grossman LLC Alerts Atara Biotherapeutics, Inc. Investors to Participate in the Class Action Lawsuit Today - ACCESS Newswire

May 22, 2026

ATRA Deadline: Rosen Law Firm Urges Atara Biotherapeutics, Inc. (NASDAQ: ATRA) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights - New Castle News

May 22, 2026